These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 28079002)

  • 21. Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs.
    Screnci D; McKeage MJ; Galettis P; Hambley TW; Palmer BD; Baguley BC
    Br J Cancer; 2000 Feb; 82(4):966-72. PubMed ID: 10732773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding.
    Ta LE; Espeset L; Podratz J; Windebank AJ
    Neurotoxicology; 2006 Dec; 27(6):992-1002. PubMed ID: 16797073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity.
    McDonald ES; Randon KR; Knight A; Windebank AJ
    Neurobiol Dis; 2005 Mar; 18(2):305-13. PubMed ID: 15686959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of platinum DNA damage-induced transcriptional inhibition in chemotherapy-induced neuronal atrophy and peripheral neurotoxicity.
    Yan F; Liu JJ; Ip V; Jamieson SM; McKeage MJ
    J Neurochem; 2015 Dec; 135(6):1099-112. PubMed ID: 26364854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lung tumour growth delay and normal tissue toxicity induced by three cytotoxic platinum drugs.
    van Rongen E; Kal HB; Kuijpers WC; van Berkel AH
    Strahlenther Onkol; 1992 May; 168(5):300-7. PubMed ID: 1598667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toxicities of the platinum antineoplastic agents.
    Markman M
    Expert Opin Drug Saf; 2003 Nov; 2(6):597-607. PubMed ID: 14585068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sensitization of cancer cells towards Cisplatin and Carboplatin by protein kinase D inhibitors through modulation of ATP7A/B (copper transport ATPases).
    Janardhanan P; Somasundaran AK; Balakrishnan AJ; Pilankatta R
    Cancer Treat Res Commun; 2022; 32():100613. PubMed ID: 35908410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients.
    Samimi G; Varki NM; Wilczynski S; Safaei R; Alberts DS; Howell SB
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5853-9. PubMed ID: 14676106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platinum compounds in children with cancer: toxicity and clinical management.
    Ruggiero A; Trombatore G; Triarico S; Arena R; Ferrara P; Scalzone M; Pierri F; Riccardi R
    Anticancer Drugs; 2013 Nov; 24(10):1007-19. PubMed ID: 23962902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs.
    Howell SB; Safaei R; Larson CA; Sailor MJ
    Mol Pharmacol; 2010 Jun; 77(6):887-94. PubMed ID: 20159940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy.
    Reed E
    Cancer Treat Rev; 1998 Oct; 24(5):331-44. PubMed ID: 9861196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients.
    Reed E; Ostchega Y; Steinberg SM; Yuspa SH; Young RC; Ozols RF; Poirier MC
    Cancer Res; 1990 Apr; 50(8):2256-60. PubMed ID: 2180564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in platinum chemotherapeutics.
    Harper BW; Krause-Heuer AM; Grant MP; Manohar M; Garbutcheon-Singh KB; Aldrich-Wright JR
    Chemistry; 2010 Jun; 16(24):7064-77. PubMed ID: 20533453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of copper and role of the copper transporters ATP7A and CTR1 in intracellular accumulation of cisplatin.
    Matsumoto S; Tanaka T; Kurokawa H; Matsuno K; Hayashida Y; Takahashi T
    Anticancer Res; 2007; 27(4B):2209-16. PubMed ID: 17695505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platinum based radiochemotherapies: Free radical mechanisms and radiotherapy sensitizers.
    Fong CW
    Free Radic Biol Med; 2016 Oct; 99():99-109. PubMed ID: 27417937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platinum compounds in the treatment of advanced breast cancer.
    Martín M
    Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs.
    Safaei R; Howell SB
    Crit Rev Oncol Hematol; 2005 Jan; 53(1):13-23. PubMed ID: 15607932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Platinum compounds: metabolism, toxicity and supportive strategies].
    Lipp HP; Hartmann JT
    Praxis (Bern 1994); 2005 Feb; 94(6):187-98. PubMed ID: 15754530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y.
    Donzelli E; Carfì M; Miloso M; Strada A; Galbiati S; Bayssas M; Griffon-Etienne G; Cavaletti G; Petruccioli MG; Tredici G
    J Neurooncol; 2004; 67(1-2):65-73. PubMed ID: 15072449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cisplatin and Oxaliplatin: Our Current Understanding of Their Actions.
    Riddell IA
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.